Is the unruptured intracranial aneurysm treatment score (UIATS) sensitive enough to detect aneurysms at risk of rupture?

Silvia Hernández-Durán1 · Dorothee Mielke1 · Veit Rohde1 · Vesna Malinova1

Received: 11 October 2019 / Revised: 2 December 2019 / Accepted: 15 January 2020 / Published online: 12 March 2020 © The Author(s) 2020

Abstract
To evaluate if the unruptured intracranial aneurysm treatment score (UIATS) is a sensitive tool to detect aneurysms at risk of rupture, we conducted an a posteriori retrospective study on ruptured intracranial aneurysms. We performed a retrospective analysis of adult patients admitted to our center from January 2010 to April 2016 with aneurysmal subarachnoid hemorrhage. The UIATS was applied to all ruptured aneurysms. Patients for whom the UIATS recommended treatment were labeled as “true positives,” whereas patients for whom the UIATS recommended observation were labeled as “false negatives.” Patients for whom the UIATS was inconclusive were excluded from the final analysis. Based on the UIATS recommendation, a sensitivity analysis was performed. A total of 262 patients with aneurysmal subarachnoid hemorrhage were screened. Of these, 212 were included in our analysis. Median age was 53 years (23–90). Most patients were females (n = 134, 63%), with an equal distribution between low-grade and high-grade hemorrhages (Hunt & Hess ≥ 3 n = 107, 50%). UIATS recommended treatment in n = 52, 25% cases (TP), was inconclusive in n = 93, 44% (excluded), and recommended observation in n = 67, 32% (FN). Based on these data, the UIATS showed a sensitivity of 44% (CI 35–53%). The UIATS exhibits rather low sensitivity for detecting aneurysms at risk of rupture.

Keywords UIATS · PHASES score · Intracranial aneurysm · Subarachnoid hemorrhage

Introduction
Unruptured intracranial aneurysms (UIA) have an approximate prevalence of 3% worldwide [31], and their management constitutes a great challenge for cerebrovascular specialists. The most feared complication of UIA is aneurysmal subarachnoid hemorrhage (aSAH), which is associated with up to 43% risk of death immediately after ictus, and 57% at 6 months [2, 15]. However, the natural history of UIA remains unclear, since no prospective cohort studies have been conducted to elucidate which one will rupture, and when [25]. The development of such studies has been deemed as unethical, for lack of treatment of UIA could result in a devastating aSAH. Therefore, knowledge about UIA derives from observational studies [17, 33].

The most relevant studies to this matter are the International Study of Unruptured Intracranial Aneurysms (ISUIA) [29] from North American and Europe, with a retrospective arm encompassing 1449 patients with 1937 UIA, and a prospective one with 4060 patients; the unruptured cerebral aneurysm study (UCAS) [11], with 5720 prospectively analyzed Japanese patients; and the study performed by Juvela et al. [13] in 142 patients harboring 181 untreated UIA between 1956 and 1978 in Finland. Based on these works, several risk factors for aneurysm rupture have been identified, such as aneurysm size and location, arterial hypertension, and smoking status.
Taking into consideration these risk factors, clinicians have performed prophylactic treatment of UIA in order to avoid the devastating consequences of aSAH, in spite of the risks associated to therapy and the lack of evidence for a clinical benefit [23]. A meta-analysis of 71 studies revealed 2% mortality at 1 month, and 4.8% of procedural unfavorable outcome in aneurysms treated endovascularly [20]. On the other hand, a meta-analysis on endovascular coiling vs. surgical clipping for UIA revealed 1% mortality and 8–9% ischemia for both treatment modalities [26].

The unruptured intracranial aneurysm treatment score (UIATS) [5] was published in April 2015 as an attempt to summarize risk factors currently considered to play a key role in aneurysm rupture and those related to treatment. The main objective of the authors was to provide clinicians with a tool to guide their decision-making (treatment vs. observation) when dealing with patients harboring UIA based on an international expert consensus. Ultimately, the main goal in the management of UIA is prevention of aSAH without submitting patients to unnecessary treatment risks. Therefore, UIA scoring systems should correctly identify patients harboring UIA in whom the risk of rupture surpasses the treatment risk. Does the UIATS achieve this goal? In this study, we attempt to answer this question.

**Methods**

In order to assess whether the UIATS is a sensitive enough tool to identify aneurysms at risk of rupture, we evaluated a cohort of patients with aSAH with the UIATS a posteriori.

We performed a retrospective analysis of consecutive adult patients admitted to our center from January 2009 to April 2016 with aSAH. Inclusion criteria comprised (a) age over 18 years and (b) aSAH caused by ruptured saccular aneurysms of the anterior or posterior circulation, confirmed by computed tomography angiography (CT-A) and/or digital subtraction angiography (DSA). Patients harboring mycotic, traumatic, fusiform, or dissecting aneurysms were excluded. Further exclusion criteria were insufficient data on patient files to assess the risk factors comprised in the UIATS.

The UIATS was applied to all ruptured aneurysms (RA). In patients with multiple aneurysms, the lesion considered to be responsible for the aSAH was the only one evaluated by means of UIATS. The risk factors considered in the UIATS are summarized in Table 1. Patients for whom the UIATS recommended treatment were labeled as “true positives (TP),” whereas patients for whom the UIATS recommended observation were labeled as “false negatives (FN).” Patients for whom the UIATS was inconclusive (cumulative scores between −2 and 2) were excluded from the final analysis. For the purposes of this study, the entire patient cohort was considered as “diseased.”

Based on the UIATS recommendation, a sensitivity test was performed. Sensitivity was defined as the ability of the UIATS to identify aneurysms at risk of rupture by recommending treatment in a cohort with proven aSAH. To estimate it, the following equation was employed: sensitivity = TP/(TP + FN).

**Results**

A total of 262 patients with SAH were screened. Of these, 212 were included in our analysis. Of the 50 patients excluded, one had a flow-associated aneurysm in the setting of an arteriovenous malformation, one had insufficient data, and 48 had either dissecting or fusiform aneurysms. Mean age was 53 years (23–90). Most patients were females (n = 134, 63%), with an equal distribution between low-grade and high-grade hemorrhages (Hunt & Hess ≥ 3, n = 107, 50%).

The most common patient-related risk factor observed in our cohort was pre-existing arterial hypertension (n = 92, 43%). No patients were of Japanese, Finnish, or Inuit origin. Furthermore, only one patient had a medical history of adult polycystic kidney disease. Illicit drug abuse were present in a minority of patients: active cigarette smoking was observed in n = 31, 15%, while current alcohol or drug abuse was reported in n = 14, 7%, and n = 3, 1%, respectively. Aneurysm multiplicity was seen in n = 67, 32%. Most patients had a life expectancy > 10 years before aSAH (n = 177, 84%). For a detailed summary of patient-related risk factors, see Table 2.

Aneurysms were predominantly located in the anterior communicating artery (ACOM) (n = 75, 35%), followed by the middle cerebral artery (MCA) (n = 48, 23%). Aneurysms in the posterior circulation were responsible for a minority of aSAH (n = 33, 16%). The most frequent aneurysm-related risk factors observed in our cohort were irregularity or lobulation (n = 108, 51%), and aspect ratio > 1.6 or size ratio > 3 (n = 51, 46%). Interestingly, aneurysms were rather small: most of them were between 4.0 and 6.9 mm in diameter (n = 86, 40%), followed by those between 7.0 and 12.9 mm (n = 81, 38%), and those < 3.9 mm (n = 28, 13%). Further aneurysm-related risk factors are summarized in Table 3.

UIATS recommended treatment in n = 52, 25% cases (TP) was inconclusive in n = 93, 44% (excluded), and recommended observation in n = 67, 32% (FN). The distribution of the UIATS results is summarized in Fig. 1. Based on these data and as illustrated in the contingency table (Table 4), the UIATS showed a sensitivity of 44% (CI 35–53%).

**Discussion**

One of the most complex questions currently faced by cerebrovascular surgeons is which UIA should be treated. To date,
there are no unequivocal criteria by which to estimate the risk of rupture of a given UIA, since several factors can interact and determine the natural history of a lesion.

In 2014, Greving et al. [7] published the PHASES score as an aid for prediction of the risk of rupture of UIA. Based on a review and pooled analysis of individual patient data from 8382 participants in six prospective trials [11, 13, 18, 28, 29, 32], the authors identified age, hypertension, history of SAH, aneurysm size, aneurysm location, and geographical region as predictors for UIA rupture. The sum of these factors then yields a 5-year rupture risk, which can guide clinicians and patients in their decision-making on whether or not a UIA should be treated.

Bijlenga et al. [1] recently published a population-based study in which they assessed whether the PHASES score would aid in identifying patients with UIA at low risk of rupture. They prospectively included 841 patients in their analysis. They were then stratified into four groups: (a) patients with stable UIA; (b) patients with growing UIA; (c) patients with treated UIA; and (d) patients with aSAH. The authors found that the odds of being diagnosed with an aSAH were associated with PHASES score > 3. In turn, a PHASES score of ≤3 was associated with a low likelihood of aneurysm rupture, thus validating this tool for estimation of UIA rupture risk.

However, the PHASES score has undergone heavy criticism because certain groups of patients were underrepresented. For example, smoking [3, 12, 27] and positive familial history of aSAH [14, 16, 21], well-established risk factors for UIA rupture, were not considered in the score. Furthermore, this score is based on pooled data from observational studies, where aneurysm treatment was left to physician’s discretion, thus rendering it subject to attrition bias. In their letter to the editor, Darsaut et al. [4] even go as far as equating the PHASES score to pseudoscience.

In a recent publication by Hilditch et al. [9], the PHASES score was evaluated in similar manner to our study in a cohort of RA. Among the 700 patients included, 17% had a PHASES score of 3 or less. The authors conclude that a considerable number of patients would have been managed conservatively had they presented incidentally prior to rupture. Consequently, the PHASES score alone should not dictate treatment decisions, since it may erroneously classify patients as low risk for rupture.

The UIATS was developed shortly after the PHASES score as a multidisciplinary consensus model, in which patient-related, aneurysm-related, and treatment-related risk factors were considered in quantitative fashion. Unlike the PHASES score, the UIATS took into consideration treatment-related risk factors, as well as aneurysm-related and patient-related risk factors, thus providing a more comprehensive assessment of all the variables that might influence treatment decision-making in UIA. Nevertheless, its aim was not to provide a prognostic nor a predictive model for UIA rupture, but a

| Risk factors considered in the UIATS | Factors favoring treatment | Factors favoring observation |
|--------------------------------------|-----------------------------|-----------------------------|
| Patient age                          | Life expectancy             | Neurocognitive disorder     |
| Previous SAH from a different aneurysm | Hypertension (systolic BP > 140 mmHg) | Coagulopathies, thrombophilic disease |
| Familial intracranial aneurysms or SAH | Aneurysm size-related risk | Psychiatric disorder        |
| Japanese, Finnish, Inuit ethnicity    | Current alcohol abuse       | Patient age-related risk    |
| Current cigarette smoking            | Cranial nerve deficit       | Aneurysm complexity-related risk |
| Hypertension (systolic BP > 140 mmHg) | Clinical or radiological mass effect | Intervention-related risk |
| Autosomal polycystic kidney disease  | Reduced quality of life due to fear of rupture | Adapted from [13] |
| Current drug abuse (cocaine, amphetamine) | Aneurysm multiplicity | |
| Current alcohol abuse                | Aneurysm maximum diameter   | |
| Cranial nerve deficit                | Aneurysm location           | |
| Clinical or radiological mass effect | Aneurysm growth on serial imaging | |
| Thromboembolic events from the aneurysm | Aneurysm de novo formation on serial imaging | |
| Epilepsy                             | Contralateral stenoocclusive vessel disease | |
reflection of contemporary practice in UIA management and guidance to clinicians treating patients with UIA.

In October 2017, Ravindra et al. [22] published a single-center validation study for the UIATS. Here, the authors scored 221 patients with UIA according to the UIATS. Subsequently, they were categorized in a contingency table assessing the UIATS recommendation versus real-world treatment decision. Percentage of misclassification, sensitivity, specificity, and area under the receiver operating characteristic (ROC) curve were calculated. In this study, the UIATS recommendation was significantly associated with the actual treatment of UIA, while sensitivity and specificity were 49% and 80%, respectively. One of the main points of criticism to this study is the calculation of sensitivity and specificity based on real-world treatment decisions within the authors’ quaternary academic medical center and the UIATS recommendation. The former assumes that those treatment decisions were correct; it presupposes that no over- or undertreatment took place in their center, and that their practice equated a sort of “gold standard.”

Similarly, our group published in February 2018 [8] an evaluation study of the UIATS, in which we attempted to elucidate whether the UIATS reflects daily clinical practice in a cerebrovascular reference center. We evaluated 93 patients harboring 147 UIA. A positive correlation coefficient of 0.366 in Spearman’s rank order was observed, thus showing accordance between our more intuitive treatment decisions and the UIATS.

The present study is the first one to assess the UIATS’ ability to identify intracranial aneurysms at risk of rupture a posteriori. While the methodology of our study was rather simple, it provides understandable data in regard to a straightforward question: could the UIATS correctly identify aneurysms at risk of rupture? Our study suggests that the UIATS does not have sufficient sensitivity to be considered a reliable tool in UIA decision-making. In almost half of our patient cohort, the UIATS failed to provide a recommendation (inconclusive cases). Additionally, almost a third of the patients were categorized as FN, since the UIATS recommended observation. Cumulatively, almost 75% of our patient cohort would have been erroneously classified. Had these patients presented incidentally before rupture, they could have succumbed to a fatal aSAH due to misclassification.

Table 2 Patient-related risk factors considered by UIATS

| Risk factor incidence | N   | %  |
|-----------------------|-----|----|
| Age                   |     |    |
| < 40 years            | 29  | 13.7|
| 40–60 years           | 120 | 56.6|
| 61–70 years           | 31  | 14.6|
| 71–80 years           | 20  | 9.4 |
| > 80 years            | 12  | 5.7 |
| Previous SAH from a different aneurysm | 0 | 0 |
| Familial intracranial aneurysms or SAH | 1 | 0.5 |
| Japanese, Finnish, Inuit ethnicity | 0 | 0 |
| Current cigarette smoking | 31 | 14.6|
| Hypertension (systolic BP > 140 mmHg) | 92 | 43.4|
| Autosomal polycystic kidney disease | 1 | 0.5 |
| Current drug abuse (cocaine, amphetamine) | 3 | 1.4 |
| Current alcohol abuse | 14 | 6.6 |
| Clinical symptoms related to UIA |     |    |
| Cranial nerve deficit | 0  | 0  |
| Clinical or radiological mass effect | 3 | 1.4 |
| Thromboembolic events from the aneurysm | 1 | 0.5 |
| Epilepsy | 1 | 0.5 |
| Other |     |    |
| Reduced quality of life due to fear of rupture | 0 | 0 |
| Aneurysm multiplicity | 67 | 31.6|
| Life expectancy due to chronic and/or malignant diseases |     |    |
| < 5 years | 19 | 8.9 |
| 5–10 years | 16 | 7.5 |
| > 10 years | 177 | 83.5|
| Comorbid disease |     |    |
| Neurocognitive disorder | 2 | 0.9 |
| Coagulopathies, thrombophilic diseases | 2 | 0.9 |
| Psychiatric disorder | 10 | 4.7 |
Of note, most of the ruptured lesions in our cohort exhibited a rather small size, which might have contributed to a lower UIATS and thus their misclassification as aneurysms amenable to observation. Furthermore, most patients were female, a risk factor for UIA rupture well described in the literature [11, 13, 29] but not considered in the UIATS. Patient age, aneurysm size, and complexity are considered twice in the UIATS: as factors favoring observation and as factors favoring treatment. This can also render the results equivocal. Additionally, the intervention-related risk is scored with a constant in the UIATS. It is well established that physician’s experience correlates with procedure risk; treatment of an aneurysm at a high-volume cerebrovascular center is not equivalent to treatment at a small institution [24].

As noted by Indrayan and Malhotra [10], a scoring system is useful only when it provides new information in regard to a complex condition and quantifies aspects that may be difficult to stratify in daily clinical assessment. Bearing this in mind, the UIATS is only useful in that it comprises complex data considered by experts when making treatment decisions for UIA. Nevertheless, it does not provide any new information.

Fahed et al. [6] offer interesting criticism to the UIATS. The authors argue that the methodology employed to develop the UIATS, namely the Delphi process, was designed for business

### Table 3

| Aneurysm-related risk factors considered by UIATS | N  | %   |
|-------------------------------------------------|----|-----|
| Maximum diameter                                |    |     |
| ≤ 3.9 mm            | 28 | 13.2|
| 4.0–6.9 mm          | 86 | 40.6|
| 7.0–12.9 mm         | 81 | 38.2|
| 13.0–24.9 mm        | 15 | 7.1 |
| ≥ 25 mm             | 2  | 0.9 |
| Morphology          |    |     |
| Irregularity or lobulation | 108 | 50.9|
| Size ratio > 3 or aspect ratio > 1.6           | 118| 55.7|
| Location            |    |     |
| Basilar bifurcation | 20 | 9.4 |
| Vertebral/basilar artery | 4  | 1.9 |
| Anterior communicating artery or posterior communicating artery | 94 | 44.3|
| Other               |    |     |
| Aneurysm growth on serial imaging               | 0  | 0   |
| Aneurysm de novo formation on serial imaging   | 1  | 0.5 |
| Contralateral stenoocclusive vessel disease     | 13 | 6.1 |

**Fig. 1** UIATS results in the present cohort. The y-axis denotes the cumulative UIATS: red dots denote scores favoring observation, while the green dots denote scores favoring treatment. The blue dots highlighted in the gray area are the cases in which the UIATS was inconclusive.
and warfare forecasting, with little relation to medical sciences. This, in turn, yields a harmonized opinion, but no facts on which to base a treatment decision in the era of evidence-based medicine. To date, scientific papers have attempted to validate both the PHASES and the UIATS in relation to their accordance with current clinical practice, assuming correctness of said practice. However, there is no way to know whether treated UIA would have ruptured and led to aSAH; the only way to know this would be in the framework of a prospective cohort study. As mentioned, such trial would pose an ethical challenge, since observation of UIA could lead to aSAH. Taking into consideration the studies mentioned in this discussion, both PHASES and UIATS offer pooled data and homogenized opinions, but no hard data on which to base treatment decisions regarding UIA.

In the last decade, hemodynamic parameters have emerged as potential markers of rupture risk in UIA. Some of these parameters include wall shear stress (WSS) and oscillatory shear index (OSI), which can be measured by computational fluid dynamics (CFD) [19]. Two of the largest studies in this respect were conducted by Xiang et al. [34] and Zhang et al. [35], including 204 and 173 aneurysms, respectively. In these papers, RA and UIA were analyzed, showing that low WSS and high OSI correlated with rupture risk. Taking into consideration that WSS has been associated with pathobiological changes in the aneurysm wall, such as disruption of the internal elastic lamina, smooth muscle cell migration, inflammatory infiltration, and loss of collagen [30], the use of these parameters in rupture risk prediction seems promising. While CFD is still being developed and refined, the incorporation of this technology can provide objective criteria to guide clinical decision-making and complement current scoring systems, such as PHASES and UIATS.

Study strengths and limitations

Our study is retrospective in nature with a relatively small patient population. The retrospective design renders the study subject to several biases, in particular, data quality assurance. Risk factors contained in the social history, such as tobacco or alcohol consumption, might not have been accurately documented. This, in turn, might have skewed the UIATS towards observation instead of treatment. A larger, prospective cohort might have yielded different results, possibly in greater accordance with the UIATS.

On the other hand, because of the methodology of our study, predictive values and specificity could not be calculated, as the entire cohort was considered as “diseased.” The former would presuppose a disease prevalence of 100%, which does not reflect the real prevalence of aSAH or UIA. Therefore, the estimation of predictive values and accuracy cannot be conducted in a reliable fashion. While this is also a potential limitation of the study, our results serve to illustrate how fallible the UIATS can be.

Conclusion

Treatment decision-making in patients with UIA remains difficult and controverted. To date, no prospective cohort studies exist to unequivocally answer the question of which UIA should be treated in order to prevent devastating aSAH. In such a dubious scientific environment, the UIATS provides a quantification of expert-assessed risk factors for UIA rupture. While useful when considering all the variables that should determine UIA treatment, the UIATS is not an empiric, mathematical model. Consequently, the UIATS should be regarded as a harmonized expert opinion on a complex subject matter, not fact. The authors thus recommend the use of UIATS as an adjunct in UIA treatment decision-making, but not as a stand-alone tool.

Funding Information

Open Access funding provided by Projekt DEAL.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval and informed consent

Upon admission, patients at our institution sign a treatment contract, in which the use of anonymized patient data for research purposes is consented to. Therefore, this study was performed in accordance with the ethical standards of our institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Open Access

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included.

Table 4 Contingency table for the UIATS

|                  | Disease present (ruptured aneurysm) | Disease absent (unruptured aneurysm) |
|------------------|-------------------------------------|--------------------------------------|
| UIATS in favor of treatment | 52 (true positive) | 0 (false positive) |
| UIATS in favor of observation | 67 (false negative) | 0 (false negative) |
| Sensitivity: 52/(52 + 67) = 44% |                        |                                     |
in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Bijlenga P, Gondar R, Schilling S, Morel S, Hirsch S, Cuony J et al (2017) PHASES score for the management of intracranial aneurysms: a cross-sectional population-based retrospective study. Stroke 48(8):2105–2112
2. Bonita R, Thomson S (1985) Subarachnoid hemorrhage: epidemiology, diagnosis, management, and outcome. Stroke 16:591–594
3. Can A, Castro V, Ozdemir Y, Dagen S, Yu S, Diligach D et al (2017) Association of intracranial aneurysm rupture with smoking duration, intensity, and cessation. Neurology 89(13):1408–1415
4. Darsaut T, Fahed R, Raymond J (2017) PHASES and the natural history of unruptured aneurysms: science or pseudoscience? J Neurointerv Surg 9:527–528
5. Etminan N, Brown R, Beseoglu K, Juvela S, Raymond J, Morita A et al (2015) The unruptured intracranial aneurysm treatment score: a multidisciplinary consensus. Neurology 85:1–9
6. Fahed R, Darsaut T (2017) The Delphi Oracle and the management of aneurysms. J Neurointerv Surg 9:e1–e2
7. Greving J, Wermer M, Brown R, Morita A, Juvela S, Yonekura M et al (2014) Development of the PHASES score for prediction of risk of rupture of intracranial aneurysms: a pooled analysis of six prospective cohort studies. Lancet Neurol 13(1):59–66
8. Hernández-Durán S, Mielke D, Rohde V, Malinova V (2018) The application of the unruptured intracranial aneurysm treatment score: a retrospective, single-center study. Neurosurg Rev 41(4):1021–1028
9. Hilditch C, Brinjikji W, Tsang A, Nicholson P, Kostynskyy A, Tymianski M et al Application of PHASES and ELAPPS scores to ruptured cerebral aneurysms: how many would have been conservatively managed? J Neurosci Sci. https://doi.org/10.23736/S0390-5616.18.04498-3
10. Indrayan A, Malhotra R (2017) Medical Biostatistics, 4th edn. Chapman & Hall/CRC Biostatistics, Boca Raton
11. Ishibashi T, Murayama Y, Utashima M (2009) Unruptured intracranial aneurysms. Incidence of rupture and risk factors. Stroke 40:313–316
12. Juvela S, Hillbom M, Numminen H, Koskinen P (1993) Cigarette smoking and alcohol consumption as risk factors for aneurysmal subarachnoid hemorrhage. Stroke 24:639–646
13. Juvela S, Poussa K, Lehto H, Porras M (2013) Natural history of unruptured intracranial aneurysms: a long-term follow-up study. Stroke:44:2414–2421
14. Kissela B, Sauerbeck L, Woo D (2002) Subarachnoid hemorrhage: a preventable disease with a heritable component. Stroke 33:1321–1322
15. Lantigua H, Ortega-Gutierrez S, Schmidt J, Lee K, Badjatia N, Agarwal S et al (2015) Subarachnoid hemorrhage: who dies, and why? Crit Care 19:309
16. Magnetic Resonance Angiography in Relatives of Patients with Subarachnoid Hemorrhage Study Group (1999) Risks and benefits of screening for intracranial aneurysms in first-degree relatives of patients with sporadic subarachnoid hemorrhage. N Engl J Med 341:1344–1350
17. Mocco J, Komotar R, Lavine S, Meyers P, Connolly E, Solomon R (2004) The natural history of unruptured intracranial aneurysms. Neurosurg Focus 17(5):E3
18. Morita A, Kirino T, Hashi K (2012) The natural course of unruptured cerebral aneurysms in a Japanese cohort. N Engl J Med 366:2474–2482
19. Murayama Y, Fujimura S, Suzuki T, Takao H (2019) Computational fluid dynamics as a risk assessment tool for aneurysm rupture. Neurosurg Focus 47(1):E12
20. Naggara O, White P, Guilbert F, Roy D, Weill A, Raymond J (2010) Endovascular treatment of intracranial unruptured aneurysms: systematic review and meta-analysis of the literature on safety and efficacy. Radiology 256:887–897
21. Raaymakers T (1999) Aneurysms in relatives of patients with subarachnoid hemorrhage: frequency and risk factors. Neurology 53:982–988
22. Ravindra V, Havenon A, Gooldy T, Scoville J, Guan J, Couldwell WT et al (2017) Validation of the unruptured intracranial aneurysm treatment score: comparison with real-world cerebrovascular practice. J Neurosurg 129(1):100–106
23. Raymond J, Guillemin F, Proust F, Molynieux AJ, Fox AJ, Claiborne JS et al (2008) Unruptured intracranial aneurysms: a critical review of the international study of Unruptured intracranial aneurysms (ISUIA) and of appropriate methods to address the clinical problem. Interv Neuroradiol 14:85–96
24. Rinaldo L, McCutcheon B, Murphy M, Shepherd D, Maloney R, Kereczoudis P (2017) Quantitative analysis of the effect of institutional case volume on complications after surgical clipping of unruptured aneurysms. J Neurosurg 127(6):1297–1306
25. Rinkel G, Algra A, Greving J, Vergouwen M, Etminan N (2017) PHASES and the natural history of unruptured aneurysms: science or pseudoscience? J Neurointerv Surg 9:618
26. Ruan C, Long H, Sun H, He M, Yang K, Zhang H et al (2015) Endovascular coiling vs. surgical clipping for unruptured intracranial aneurysm: a meta-analysis. Br J Neurosurg 29(4):485–492
27. Shuie I, Arima H, Hankey G, Anderson C (2012) Modifiable lifestyle behaviours account for most cases of subarachnoid hemorrhage: a population-based case-control study in Australasia. J Neurol Sci 313:92–94
28. Sonobe M, Yamazaki T, Yonekura M, Kikuchi H (2010) Small unruptured intracranial aneurysm verification study: SUAve study, Japan. Stroke 41:1969–1977
29. The international study of unruptured intracranial aneurysms investigators (1998) Unruptured intracranial aneurysms - risk of rupture and risks of surgical intervention. N Engl J Med 339(24):1725–1733
30. Tulamo R, Frösen J, Hermesniemi J, Niemela M (2018) Inflammatory changes in the aneurysm wall: a review. J Neurointerv Surg 10(Suppl 1):i58–i67
31. Vlak M, Algra A, Brandenburg R, Rinkel G (2011) Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta-analysis. Lancet Neurol 10:626–636
32. Wermer M, van der Schaaf I, Veltbuis B, Majoie C, Albrecht K, Kinkel G (2006) Yield of short-term follow-up CT/MR angiography for small aneurysms detected at screening. Stroke 37:418–428
33. Wiebers D (2003) Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet 362(9378):103–110
34. Xiang J, Yu J, Snyder KV, Levy EI, Siddiqui AH, Meng H (2016) Hemodynamic-morphological discriminant models for intracranial aneurysm rupture remain stable with increasing sample size. J Neurointerv Surg 8:104–110
35. Zhang Z, Jing L, Liu J, Li C, Fan J, Wang S et al (2016) Clinical, morphological, and hemodynamic independent characteristic factors for rupture of posterior communicating artery aneurysms. J Neurointerv Surg 8:808–812

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.